7-Deazaguanosine also caused significant activation of natural killer and phagocytic cells but did not augment T-and B-cell blastogenesis. Intraperitoneal treatments of 50, 100, and 200 mg/kg/day administered 24 and 18 h before virus inoculation were highly protective in mice inoculated with lethal doses of Semliki Forest or San Angelo viruses. Less but still significant survivor increases were evident in treated mice infected with banzi or encephalomyocarditis viruses. In most cases, the degree of antiviral activity was similar to that exhibited by the biological response modifier 7-thia-8-oxoguanosine. 7-Thia-8-oxoguanosine was more potent than 7-deazaguanosine against encephalomyocarditis virus in mice, however. Oral efficacy was achieved with 7-deazaguanosine treatments of 2100 mg/kg against all virus infections, whereas 7-thia-8-oxoguanosine is reported to be devoid of oral activity in rodents. Thus, 7-deazaguanosine represents the first reported orally active nucleoside biological response modifier exhibiting broad-spectrum antiviral activity against particular types of RNA viruses.
Recently 7-thia-8-oxoguanosine (TOGuo) was reported to be a novel biological response modifier active against a broad spectrum of viruses in vivo (6, 14, 15) . TOGuo has no in vitro antiviral activity against a large number of DNA and RNA viruses, however. The effects in animals are primarily due to interferon induction (16, 17) , although natural killer (NK) cells (6, 16) , lymphocytes (6) , and macrophages (3, 7) are also activated. The role of interferon in combating acute virus infections has been well documented (5, 8) , whereas activated cells of the immune system, although necessary in the overall fight against virus infections, seem to play a lesser role (1, 21) .
One property that is lacking in TOGuo is its oral bioavailability in rodent models (15) . If this were to apply to humans, TOGuo would be limited in its use for treatment of virus infections. Presently, it has not undergone sufficient toxicology trials to conduct oral bioavailability studies in humans. In the meantime, we have synthesized related nucleosides in an effort to identify those that may be orally active. Our previous work showed that certain guanosine analogs substituted at positions 7 and 8 (using purine nomenclature) have antiviral properties by virtue of immune activation (6) . In the present report, we describe the first orally active compound of this type, 7-deazaguanosine (7-dzGuo), which has antiviral activity in mice against a variety of RNA viruses but lacks antiviral properties in cell culture.
MATERIALS AND METHODS
Compounds. 7-dzGuo and TOGuo (Fig. 1) were synthesized at the ICN Nucleic Acid Research Institute by previously published procedures (6, 9) . The compounds were dissolved in 2% sodium bicarbonate (pH 8.6 to 8.9) to * Corresponding author. achieve good solubility, as previously indicated for TOGuo (15) . At 400 mg/kg of body weight, 7-dzGuo was administered as a suspension. Bicarbonate served as the placebo control for all animal experiments. 8-Bromoguanosine 10 min, and half of the medium (100 ,ul) was counted in a gamma counter. Untreated controls consisted of target cells not exposed to effector cells (spontaneous counts released) and cells treated with 1% Triton X-100 (maximum counts released). The percent cytotoxicity for each sample was the (experimental counts -spontaneous counts)/(maximum counts -spontaneous counts) x 100. Cytotoxicity differences between the placebo controls and 7-dzGuo-treated groups were statistically analyzed by using the two-tailed Student t test.
To evaluate drug effects on phagocytic activity, 20-g mice were pretreated i.p. with 1 ml of 3% thioglycolate medium (Difco Laboratories, Detroit, Mich.) 4 to 5 days before treatment. Nucleosides were injected i.p. into animals, and 4 h later cells from peritoneal exudate were removed and assayed for luminol-dependent chemiluminescence (CL). CL was determined essentially as described by Cheung et al. (2) , with slight modifications. Briefly, measurements of CL (recorded in counts per minute) were made with a Beckman liquid scintillation counter fitted with a single photon monitor. The reaction mixtures consisted of 2 ml of cell suspension in HBSS (106 cells per ml), 250 ,uM luminol, and 2 mg of zymosan (when used). The maximal CL over a 5-min time interval was recorded for each sample, and the mean of four time intervals over preset times (see Table 2 ) was calculated. The data was expressed as mean stimulation indices, which are defined as the CL produced by cells from the peritoneal exudate of mice treated with nucleoside divided by the CL of cells from placebo-treated mice. In each case, the effect of nucleoside treatment with or without zymosan was compared with the respective placebo control (with or without zymosan). Zymosan itself caused a fourfold stimulation of CL relative to the placebo group of cells not treated with zymosan. Enhancement of phagocytic activity was statistically analyzed by the two-tailed Student t test. This assay primarily measures respiratory burst activity of macrophages, which are the predominant cell type in the peritoneal exudate (7) .
Spleen cell blastogenesis in vitro assays using [3H]thymidine incorporation were performed as described previously (6), using concanavalin A (20 ,ug/ml) and lipopolysaccharide (50 pLg/ml) to differentiate T and B cells, respectively (10) . These concentrations of mitogens were optimal in our system for augmenting blastogenic responses. Approximately 105 cells per well were exposed to nucleoside and mitogens for 2 days. After 1 day, [3H]thymidine (5 ,uCi/ml) was added to measure DNA synthesis. Cells harvested after 2 days were counted for incorporated radioactivity.
Animal models and experiments. The virus infection models that were used have been previously described by us and others for banzi (18) , EMC (12) (14, 15) , indicating that doses split in half and given 24 and 18 h before virus challenge were highly effective. Also, preliminary experiments performed with 7-dzGuo (not presented in this report) established the range of effective doses. Toxicity studies performed in uninfected mice (5 mice per group) assessed death and weight loss parameters. All experiments ran for 21 days, at which time the animals were considered cured from the lethal phase of each infection. Statistical evaluations compared drug-treated groups with respective placebo controls. Increases in survival numbers were evaluated by the two-tailed Fisher exact test. Mean survival time increases were statistically analyzed by the two-tailed MannWhitney U test.
RESULTS
Toxicity. The toxicity of 7-dzGuo was evaluated in uninfected mice treated with different doses under conditions that were used in antiviral experiments. Doses as high as 200 mg/kg administered i.p. or 400 mg/kg p.o. given in divided daily doses for 1 day caused no death, weight loss, or inhibition of weight gain. However, in follow-up studies designed to assess toxicity from longer courses of treatment, 100-mg/kg doses given for 1 week were lethal to mice. These results indicate that cumulative toxicity occurs with repeated administration of compound.
Interferon induction and immune activation. The ability of 7-dzGuo to induce interferon in mice following single p.o. and i.p. inoculations was determined (Fig. 2) . Interferon induction was rapid, and high levels (-105 U/ml) were detected in serum 1 to 4 h after administration of the VOL. 35, 1991 NK cell activity was augmented in spleens from mice treated with 7-dzGuo (Fig. 3) (6) . Varying the amounts of each mitogen and extending the time of incubation did not change these results.
Animal infection experiments. Because of its interferoninducing effect, 7-dzGuo was evaluated further for antiviral activity in animal infection models. For these studies, TOGuo was run as a positive control for comparative purposes. Against Semliki Forest virus, i.p. treatments with 7-dzGuo protected the majority of mice from mortality at 50 and 100 mg/kg, but 200 mg/kg was somewhat less effective (Table 2) . By oral administration, the nucleoside induced protection at 200 mg/kg, but not at 100 mg/kg. TOGuo was effective i.p. at 100 mg/kg in this experiment. For either compound, the mean survival time was not extended by drug treatment relative to that for the placebo control.
Against San Angelo virus, 7-dzGuo was highly active at 25 to 100 mg/kg i.p. or 100 and 200 mg/kg p.o. and increased the numbers of survivors (Table 3) . TOGuo was also protective to mice at 100 mg/kg i.p. In this model it appeared that the mean survival times were longer in 7-dzGuo-treated mice than in the placebo control, although there were not sufficient numbers of dead mice to statistically evaluate the results.
The two compounds were also evaluated for their ability to treat banzi virus infections in mice (Table 4 ). This infection is quite severe, and previous studies have shown that it is difficult to achieve a high cure rate (14, 15) . Doses of 7-dzGuo administered i.p. at 50 to 200 mg/kg caused moderate but statistically significant increases in survival, which was roughly equivalent to the effects of 50 to 100 mg of TOGuo per kg. By p.o. administration, 7-dzGuo reduced mortality by 50% at 400 mg/kg but had no effect at 200 mg/kg. Doses of each compound were able to extend the mean survival time significantly compared with that for the placebo control.
Two experiments were conducted to evaluate the activities of the nucleosides against EMC virus infections (Table  5 ). In the first experiment, 7-dzGuo was highly protective at 50 mg/kg i.p. but not at 100 and 200 mg/kg. Doses of 200 and 400 mg/kg given p.o. provided only moderate survival increases. In contrast, TOGuo gave excellent protection i.p. at 50, 100, and 200 mg/kg. Because of these unexpected results, the second experiment was performed to substantiate the initial data. Doses of 25 to 200 mg of 7-dzGuo per kg administered i.p. produced only moderate increases in survival, whereas 100 mg of TOGuo per kg was highly active. In this latter experiment, doses of 7-dzGuo significantly extended the mean survival time. These results confirm that 7-dzGuo was not as effective as TOGuo against EMC virus infections in mice and suggest that the second EMC virus experiment may be more consistent in terms of representing the efficacy of 7-dzGuo in this model.
DISCUSSION
The results of these studies show that 7-dzGuo induced high levels of interferon in the sera of mice. These titers persisted for 1 to 4 h and then declined slowly. Compared with TOGuo (16, 17), 7-dzGuo induced an increase of at least 1 order of magnitude in the interferon titer, and the rate of decline of interferon in the 7-dzGuo-treated mice was slower. Both agents induced a rapid (within 1 h of treatment) production of interferon. Recent work has shown that interferon induction is of major importance in the antiviral activity of TOGuo against Semliki Forest (16) and Punta Toro (17) virus infection in mice. In both models, antibody to alpha/beta interferon completely abrogated the protective effect of treatment. This is most likely the case with 7-dzGuo, since the compound showed no antiviral activity (at .320 ,uM) against any of the viruses reported here (and many other DNA and RNA viruses) in cell culture.
By comparing the NK cell activation data presented here and elsewhere (6, 16), 7-dzGuo and TOGuo have similar potencies. 7-dzGuo was more active than TOGuo in stimulating activity in cells from peritoneal exudate, however. Whether this effect translates into an enhanced ability to engulf or otherwise kill virus-infected cells was not determined. 7-dzGuo was not capable of enhancing T-and B-cell blastogenesis, whereas TOGuo is a potent activator of these mitogen-induced cells (6; also unpublished studies). These on October 28, 2017 by guest http://aac.asm.org/ Downloaded from results suggest that the oxygen atom at position 8 (purine nomenclature) of TOGuo (or bromine atom in the case of 8-BrGuo, which also enhances spleen cell blastogenesis [6] ), is important for activating blastogenesis. 7-dzGuo possesses only a hydrogen at position 8.
For the assays of interferon production and NK cell activity, both p.o. and i.p. doses were shown to exert a biological effect. A higher p.o. dose was required to achieve the same degree of activity as was seen with i.p. treatments. These results correlate with the antiviral experiments.
7-dzGuo was similar to TOGuo in its antiviral spectrum of activity, being effective in vivo against four types of RNA viruses. In an i.p. treatment regimen, the two compounds exhibited similar potencies against banzi, San Angelo, and Semliki Forest virus infections, but the latter compound was superior against EMC virus in mice. By comparing the profiles of immune activation of the two compounds, TOGuo was found to enhance spleen cell blastogenesis, whereas 7-dzGuo did not. Perhaps this immunoenhancement by TOGuo contributed to its anti-EMC virus activity. In experiments (unpublished studies conducted in our laboratory) with mice infected by other viruses, 7-dzGuo was inactive against influenza B virus and only weakly active against vesicular stomatitis virus, two viruses of public health and veterinary importance, respectively. We excluded retroviruses and certain DNA viruses (herpes simplex virus and cytomegalovirus) from these evaluations, because 7-dzGuo appears to have a spectrum of antiviral activity similar to that of TOGuo (14, 15) , and TOGuo is inactive or weakly active against these viruses.
Under the treatment regimen employed, 7-dzGuo was not toxic to mice by either i.p. or p.o. administration, yet it showed good antiviral activity in the range of 25 to 200 mg/kg (i.p.) and 200 to 400 mg/kg (p.o.). The lower limits of effective doses depended upon the virus infection model, with San Angelo virus being most sensitive to the antiviral action of 7-dzGuo. This is also the case for TOGuo (14, 15) . Since the cumulative toxicity of 7-dzGuo with repeated daily dosing is a concern, new analogs of this nucleoside are in the process of being evaluated in an attempt to dissociate toxicity from immunopotentiative properties.
Interferon inducers have generally shown a greater lack of dose responsiveness (14, 15) or erratic survival patterns from dose to dose (such as experiment 1 in Table 5 ) than strictly antiviral agents. This may be due to variability in response from mouse to mouse. In these experiments, 7-dzGuo was evaluated against each virus two or more times. Within variable limits, the mortality data presented in Tables 2  through 4 and experiment 2 in Table 5 are usually expected under the conditions (age and species of mouse, virus challenge dose, routes of virus and drug administration) that were used.
Studies conducted with TOGuo indicate that early treatments during the course of infection are essential to achieve adequate protection from mortality (15) . Likewise, multiple days of treatment do not lead to enhancement of antiviral activity. Using banzi and EMC virus models, multiple days of treatment with 7-dzGuo did not lead to increases in antiviral activity either (unpublished results). These data suggest that the therapeutic utility of 7-dzGuo may be limited. Apparently the early activation of the immune system with interferon induction provides a threshold of protection that is not further augmented by repeated applications. This phenomenon applies to other interferon inducers (22) . Also, hyporeactivity to interferon inducers occurs by repeated administration of compounds (20) and as a result of certain virus infections (19) . It is highly probable that repeated treatments with 7-dzGuo will lead to hyporesponsiveness, although this has yet to be investigated.
A significant effect of 7-dzGuo in these experiments was its oral activity, which TOGuo does not exhibit (15 
